Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hologene 7 in Recessive Dystrophic Epidermolysis Bullosa
NCT02984085Phase 2Terminated
- Sponsor
- Holostem
- Start
- Jan 2017
- Primary completion
- Aug 2018
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in Recessive Dystrophic Epidermolysis Bullosa (RDEB), sponsored by Holostem. Primary endpoint: Safety at 3 months. Started Jan 2017; status: terminated.
02
Conditions
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Beyond the preview
Go deeper on NCT02984085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02984085.